Kliogest (Norethisterone Acetate, Estradiol)

Norethisterone acetate acts as a synthetic progestogen that suppresses the mid‑cycle surge of luteinising hormone and follicle‑stimulating hormone, thereby preventing ovulation. Estradiol, a natural estrogen, stabilises the endometrium and, together with the progestogen, alters cervical mucus and the uterine lining to reduce the chance of fertilisation and implantation.

The dosage regimen for Kliogest is set by a qualified prescriber based on the patient’s medical history, age, and any concomitant medications. The prescribing information provides guidance, but the exact dose and schedule must be individualized by the healthcare professional.

Kliogest is classified as pregnancy category X, meaning it is contraindicated during pregnancy because it may cause fetal harm. It is also not recommended for breastfeeding women, as hormonal components can be excreted in breast milk and may affect the infant.

To order Kliogest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. The sales team will verify trade or institutional credentials and then provide pricing, availability, shipping details and any required import documentation.

Kliogest contains norethisterone acetate and estradiol, a formulation that offers a balance of progestogenic and estrogenic activity similar to many other combined oral contraceptives. Compared with products that use ethinyl‑estradiol, estradiol may have a different metabolic profile, potentially influencing side‑effect patterns and cardiovascular risk, but overall efficacy in preventing pregnancy is comparable.

Kliogest tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and heat. Keep the medication out of reach of children and do not use after the expiry date printed on the packaging.

Kliogest is taken orally, usually once daily at the same time each day, as directed by the prescribing clinician. The typical regimen follows a cyclic schedule of active tablets followed by a hormone‑free interval, but the exact pattern should be confirmed with the healthcare provider.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, and stroke, particularly in women with pre‑existing risk factors. Severe allergic reactions and liver dysfunction are also rare but potentially life‑threatening complications that require immediate medical attention.

Kliogest should not be used by women who are pregnant, breastfeeding, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, known or suspected hormone‑dependent tumors, or who smoke cigarettes and are over 35 years of age. Contraindications are detailed in the prescribing information.